TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04316793

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling (SN)
Description: Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
Study: NCT01743066

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: vitamin E (200 IU, caplet) daily orally for 20 weeks
Study: NCT00426842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
Study: NCT00582764

Intervention type: OTHER
Intervention: perform dynamic contrast enhanced (DCE) MRI
Description: With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
Study: NCT02229513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Cooling
Description: Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
Study: NCT03013335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent
Study: NCT01932866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetic risk score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetic risk score
Study: NCT02965040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral
Study: NCT03792178

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nano resin composite
Description: Dental composite material
Study: NCT01368484

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: 1500 mg sunflower/day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexanoic acid
Description: 1500mg/day for 10 weeks
Study: NCT02341222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP self-standing felt device
Description: BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PR Parietene mesh device
Description: Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
Study: NCT02166684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Do-it-yourself devices
Description: Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120.
Study: NCT02450084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
Study: NCT02452476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5633
Description: Rescue treatment (if needed)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: Rescue treatment (if needed)
Study: NCT01134432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone + mabthera
Description: Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks
Study: NCT02195804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride ODT
Description: Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride ODT RM
Description: Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine hydrochloride
Study: NCT01158209

Intervention type: PROCEDURE
Intervention: Endocervical samples
Description: Endocervical samples collection during routine gynaecological examinations.
Study: NCT03208439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lower-limb cycling system
Description: patients will receive 30-minute cycling exercise

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: lower-limb cycling system
Description: patients will receive 30-minute cycling exercise
Study: NCT01548742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Group Therapy (PCGT)
Description: Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
Study: NCT05172674

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound according routine antenatal care
Description: ultrasound examinations at 11-14, 19-22 and 33-35 weeks

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound according routine antenatal care
Description: ultrasound examinations at 11-14, 19-22 and 33-35 weeks
Study: NCT00637572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Description: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate oral suspension 40 mg/mL
Description: Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
Study: NCT01761812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI with gadofosveset and MR elastography
Study: NCT04033068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two MV-ZIKA-RSP vaccinations (high dose)
Description: In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two MV-ZIKA-RSP vaccination (low dose)
Description: In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One MV-ZIKA-RSP vaccination (high dose) and one placebo
Description: In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo
Study: NCT02929823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose SJP-0035 Ophthalmic Solution
Description: 0.001% SJP-0035 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose SJP-0035 Ophthalmic Solution
Description: 0.0002% SJP-0035 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of SJP-0035 Ophthalmic solution
Description: 0% SJP-0035 Ophthalmic Solution
Study: NCT02450084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
Study: NCT01134432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
Study: NCT03579342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology and active coaching to improve lifestyles behaviors
Description: Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology to improve lifestyle behaviors
Description: Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
Study: NCT01581125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep:wake 1
Description: Sleep and Wake durations for arm 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep:wake 2
Description: Sleep and Wake durations for arm2
Study: NCT02096432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Activation
Description: Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Community Care
Description: Community standard care as usual
Study: NCT04033068

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Two placebo injection
Description: In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo
Study: NCT04145310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-04 + SCO
Description: sublingual drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SCO
Description: sublingual drops
Study: NCT02917161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (PAE)
Description: PAE is performed 6 weeks before radical prostatectomy
Study: NCT04045314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical moisturizer
Description: The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
Study: NCT00893269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: Oral capsule at dose recommended for adults

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo prior to sleep
Study: NCT00897390

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Tablet, Oral, 2.5 mg, Once Daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Tablet, Oral, 2.5 mg, Once Daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin IR (glucophage)
Description: Tablets, Oral, 1000 mg, Once Daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin IR (glucophage)
Description: Tablets, Oral, 1000 mg, Once Daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin + Metformin IR (FDC)
Description: Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
Study: NCT02856633

Intervention type: DEVICE
Intervention: Vitaliti
Study: NCT01474044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastropylor Complex Capsules
Description: 3 pills, three times a day, after meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo that is same as gastropyloric complex capsules
Study: NCT00897390

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin + Metformin IR (FDC)
Description: Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
Study: NCT02657460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor derived microparticles
Description: The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cisplatin
Description: cisplatin is a traditional drug for lung cancer
Study: NCT04461015

Intervention type: DRUG
Group type: OTHER
Intervention: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
Description: Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min

Intervention type: DRUG
Group type: OTHER
Intervention: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
Description: Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min

Intervention type: DRUG
Group type: OTHER
Intervention: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
Description: Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
Study: NCT01458028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: Single doses of 20 mg BAY85-3934 as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
Study: NCT00491374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
Study: NCT01744314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin and Pantoprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose powder tablets
Study: NCT01975610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: 375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 28 days
Study: NCT03175146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 5 treatments given over 2 weeks
Study: NCT02476136

Intervention type: DRUG
Intervention: paroxetine, duloxetine, fluoxetine or venlafaxine
Study: NCT03911024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV
Description: At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health
Description: Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
Study: NCT02440789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.
Study: NCT02105545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Treatment Options
Description: Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
Study: NCT03561935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propafenone
Description: prescribing propafenone for the management of premature ventricular complex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indenol
Description: prescribing indenol for the management of premature ventricular complex
Study: NCT03087474

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01700127

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Description: breastfeeding encouraged versus withheld

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding
Description: breastfeeding encouraged versus withheld
Study: NCT04220645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opportunstic treatment
Description: opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Referral at discharge
Study: NCT02522091

Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI
Study: NCT02450084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: IV-PCA containing Fentanyl
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA containing Fentanyl
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
Study: NCT04901585

Intervention type: PROCEDURE
Intervention: Totally intracorporeal distal gastrectomy
Description: Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
Study: NCT04155814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Injection
Description: USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer Injection
Description: (Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
Study: NCT00359723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Study: NCT01447121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tatsu/Tradewind Investigational BG Monitoring System
Description: Tradewind is a Bayer investigational meter that used an investigational sensor.